ALK Abello Secures 40% Tablet Capacity Boost via Catalent Deal…

Event summary

ALK Abello expands long-term partnership with Catalent for Zydis® fast-dissolving tablet technology.
Agreement increases annual tablet capacity by ~40% to 1.1 billion units starting in the early 2030s.
ALK to invest DKK 500 million over three years for capacity expansion at Catalent's UK and Canada sites.
Deal secures supply for current and future SLIT tablet portfolio, including potential peanut/tree nut allergy treatments.

The big picture

This deal underscores ALK's focus on supply chain robustness amid growing demand for allergy treatments. The partnership, spanning over two decades, highlights the stability of ALK's business model without patent cliffs. The investment in Catalent's Zydis® technology positions ALK to capture future market opportunities in sublingual immunotherapy.

What we're watching

Execution Risk: Whether ALK can integrate the expanded capacity without operational disruptions.
Market Demand: The pace at which demand grows for ALK's SLIT tablet portfolio, particularly for peanut/tree nut allergy treatments.
Cost Dynamics: How future manufacturing costs will offset the DKK 500 million investment over the contract duration.